- Home
- THAR vs MNOV Comparison
THAR vs MNOV Comparison
Compare THAR & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | THAR | MNOV |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.1M | 76.5M |
| IPO Year | 2022 | 2005 |
Fundamental Metrics
Financial Performance| Metric | THAR | MNOV |
|---|---|---|
| Price | $2.39 | $1.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $17.00 | $7.00 |
| AVG Volume (30 Days) | ★ 292.1K | 103.8K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $257,917.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $1.13 |
| 52 Week High | $9.08 | $2.24 |
Technical Indicators
Market Signals| Indicator | THAR | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 41.60 | 55.22 |
| Support Level | $2.36 | $1.48 |
| Resistance Level | $2.75 | $1.60 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 16.00 | 60.53 |
Price Performance
Historical ComparisonAbout THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.